Associação brasileira de hematologia, hemoterapia e terapia celular consensus on genetically modified cells. V: manufacture and quality control

Santis, Gil Cunha De; Langhi Junior, Dante Mário; Feitoza, Andreza; Junior, Alfredo Mendrone; Kutner, José Mauro; Covas, Dimas Tadeu; Couto, Samuel Campanelli Freitas; Guerino-Cunha, Renato L.; Orellana, Maristela Delgado; Rizzo, Sílvia Renata Cornelio Parolin.
Hematol Transfus Cell Ther, v. 43, suppl 2, p. S35-S41 nov. 2021
Artículo en Inglés | SES-SP, SESSP-IBPROD, SES-SP | ID: bud-4000

Documentos relacionados

  1. Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. V: Manufacture and quality control.
  2. Treatment of secondary CNS lymphoma using CD19-targeted chimeric antigen receptor (CAR) T cells.
  3. A simple and effective method to purify and activate T cells for successful generation of chimeric antigen receptor T (CAR-T) cells from patients with high monocyte count.
  4. Challenges of clinical translation from single-cell sequencing to measures in clinical biochemistry of haematology: Definition of immune cell identities.
  5. Spacer Length Modification Facilitates Discrimination between Normal and Neoplastic Cells and Provides Clinically Relevant CD37 CAR T Cells.
  6. Immune effector cell-associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations.
  7. Anti-CD79b/CD3 bispecific antibody combined with CAR19-T cells for B-cell lymphoma treatment.
  8. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA).
  9. Structural details of monoclonal antibody m971 recognition of the membrane-proximal domain of CD22.
  10. Manufacturing chimeric antigen receptor T cells from cryopreserved peripheral blood cells: time for a collect-and-freeze model?